Journal Watch · Frontiers in Immunology · 2026

KRAS G12C inhibitors in KRAS<sup>G12C</sup>-mutated solid tumors: an immunologically informed systematic review and reconstructed individual patient data meta-analysis.

These subgroup observations are hypothesis-generating and require prospective validation.<h4>Systematic review registration</h4>https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251146769.

Yan Y, Zheng L, Wang H et al.Frontiers in Immunology3 min readPharma relevance 85/100

DOI: 10.3389/fimmu.2026.1848431PMID: 42500683Study type: randomised / controlled clinical trial

TL;DR

These subgroup observations are hypothesis-generating and require prospective validation.<h4>Systematic review registration</h4>https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251146769.

Key findings

  • Regarding PD-L1 expression, PFS benefits were observed in patients with expression levels <1% (HR, 0.56; 95% CI: 0.38-0.83; <i>P</i> = 0.004) and 1%-49% (HR, 0.58; 95% CI: 0.43-0.78; <i>P</i> < 0.001).
  • KRAS G12Ci demonstrated a better safety profile, apart from diarrhea and rash.<h4>Conclusions</h4>A similar OS, but better PFS and ORR with a superior safety profile were observed in patients receiving KRAS G12Ci, suggesting that KRAS G12Ci may be more suitable for later-line therapy.
  • Older patients, those without liver metastases, or those with PD-L1<50% may be the target population.
  • These subgroup observations are hypothesis-generating and require prospective validation.<h4>Systematic review registration</h4>https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251146769.

Numbers at a glance (from the abstract)

95%39.7%1%49%50%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

In 1-stage reconstructed individual patient data meta-analyses, PFS was better in the KRAS G12Ci group (HR, 0.62; 95% CI, 0.53-0.74; <i>P</i> < 0.001). However, no statistical difference in OS was observed (HR, 0.93; 95% CI, 0.74-1.16; <i>P</i> = 0.495). The results were confirmed by 2-stage meta-analyses which additionally exhibited an objective response rate (ORR) of 3.60 (95% CI; 2.01-6.46; <i>P</i> < 0.001; I<sup>2</sup> = 39.7%).

Full abstract (original)

Background: <h4>Background</h4>Despite the proven efficacy of KRAS G12C inhibitors (KRAS G12Ci) in solid tumors, evidence from direct comparisons with standard of care is scarce, and no analysis has investigated the potential immunological basis for differential responses.<h4>Methods</h4>PubMed, Embase, Cochrane Library, and ClinicalTrials.gov for randomized controlled trials (RCTs) involving solid tumors patients who had received KRAS G12Ci were retrieved from inception to March 28, 2026. Individual participant data on progression-free survival (PFS) and overall survival (OS) were extracted from the published Kaplan-Meier survival curves. When available, subgroup data by programmed death ligand 1 (PD-L1) expression were extracted to explore immune-related correlates of treatment response.<h4>Results</h4>A total of 4 articles with 3 RCTs and 949 participants were selected.

What they did: In 1-stage reconstructed individual patient data meta-analyses, PFS was better in the KRAS G12Ci group (HR, 0.62; 95% CI, 0.53-0.74; <i>P</i> < 0.001). However, no statistical difference in OS was observed (HR, 0.93; 95% CI, 0.74-1.16; <i>P</i> = 0.495). The results were confirmed by 2-stage meta-analyses which additionally exhibited an objective response rate (ORR) of 3.60 (95% CI; 2.01-6.46; <i>P</i> < 0.001; I<sup>2</sup> = 39.7%).

Results & conclusions: Regarding PD-L1 expression, PFS benefits were observed in patients with expression levels <1% (HR, 0.56; 95% CI: 0.38-0.83; <i>P</i> = 0.004) and 1%-49% (HR, 0.58; 95% CI: 0.43-0.78; <i>P</i> < 0.001). KRAS G12Ci demonstrated a better safety profile, apart from diarrhea and rash.<h4>Conclusions</h4>A similar OS, but better PFS and ORR with a superior safety profile were observed in patients receiving KRAS G12Ci, suggesting that KRAS G12Ci may be more suitable for later-line therapy. Older patients, those without liver metastases, or those with PD-L1<50% may be the target population. These subgroup observations are hypothesis-generating and require prospective validation.<h4>Systematic review registration</h4>https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251146769.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1848431 · PubMed 42500683.

Why it matters for pharma & biotech

  • Directly relevant to teams in targeted oncology / immuno-oncology, small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: targeted oncology / immuno-oncology · small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Frontiers in Immunology study find?

These subgroup observations are hypothesis-generating and require prospective validation.<h4>Systematic review registration</h4>https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251146769.

What type of study is this?

It is a randomised / controlled clinical trial, published in Frontiers in Immunology in 2026. In 1-stage reconstructed individual patient data meta-analyses, PFS was better in the KRAS G12Ci group (HR, 0.62; 95% CI, 0.53-0.74; <i>P</i> < 0.001).

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1848431. PubMed ID: 42500683. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Yan Y, Zheng L, Wang H et al.. KRAS G12C inhibitors in KRAS&lt;sup&gt;G12C&lt;/sup&gt;-mutated solid tumors: an immunologically informed systematic review and reconstructed individual patient data meta-analysis.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1848431.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/kras-g12c-inhibitors-in-kras-lt-sup-gt-g12c-lt-sup-gt-mutated-solid-tumo-848431/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides